Actualités Argen X SE - ARGX | Actions Euronext

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

ADHERE was largest and most innovative clinical trial of CIDP patients to date VYVGART® Hytrulo (efgartigimod...

argenx to Present at Upcoming Investor Conferences

August 28, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

$478 million in second quarter global net product sales First CIDP patients treated with VYVGART® Hytrulo...

argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

July 18, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company...

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

First and only NMPA-approved subcutaneous injectable FcRn blocker for gMG patients in China Consistent...

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

ARDA study data show potential for empasiprubart to drive functional improvement and reduced risk of relapse...

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART® Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory...

argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024

R&D Day presentations to include recent Phase 2 datasets in Sjogren’s disease (efgartigimod) and...

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years...

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable...

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Argen X SE (ARGX)

Votre Hub pour des idées et discussions en direct en temps réel

ARGX Actualités

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

argenx to Present at Upcoming Investor Conferences

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024

argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

argenx announces results of Annual General Meeting of Shareholders

argenx to Present at BofA Securities 2024 Health Care Conference

argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Argen X SE (ARGX) Actualités

Argen X SE (ARGX)

Votre Hub pour des idées et discussions en direct en temps réel

ARGX Actualités

argenx Announces Publication in The Lancet Neurology of Pivotal ADHERE Study Data in Chronic Inflammatory Demyelinating Polyneuropathy

argenx to Present at Upcoming Investor Conferences

argenx Reports Half Year 2024 Financial Results and Provides Second Quarter Business Update

argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024

argenx and Zai Lab Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China

argenx Highlights Breadth of Autoimmune Pipeline with New Multifocal Motor Neuropathy Data at 2024 Peripheral Nerve Society Annual Meeting

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

argenx to unveil its ‘Vision 2030: Taking Breakthrough Science to 50,000 Patients’ during its Upcoming R&D Day on July 16, 2024

argenx to Present at Goldman Sachs 45th Annual Global Healthcare Conference

argenx Reports First Quarter 2024 Financial Results and Provides Business Update

argenx announces results of Annual General Meeting of Shareholders

argenx to Present at BofA Securities 2024 Health Care Conference

argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024

argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease

argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application